The high prevalence of mortality and morbidity due to cardiovascular diseases (CVDs) indicates that there is a large unmet medical need for new and effective agents that are also well tolerated and safe, especially for patients unable to either tolerate statins or achieve optimal low-density lipoprotein cholesterol (LDL-C) which is a major risk factor of myocardial infarction and stroke. There is evidence that proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration might accelerate atherosclerosis by promoting inflammation, endothelial dysfunction, and hypertension by mechanisms independent of the LDL receptor. Recent clinical trials with PCSK9 inhibitor monoclonal antibodies indicate that with present doses and mode of administration, substantial benefit can be achieved in reducing cardiovascular events with modest reduction in mortality. There is an unmet need to find out PCSK9 metabolism in relation to other risk factors of CVDs, with respect to PCSK9 concentrations according to time structure. This is important because LDL receptor activity and synthesis of cholesterol in the hepatocyte as well as PCSL9 gene activity may be circadian periodic. It is possible that knowledge about circadian concentration of PCSK9, every 4 hours, according to time structure may provide information about its circadian bioavailability and bioactivity. An agent may be highly bioavailable but may not be bioactive due to circadian dysfunction. Chronotherapy with PCSK9 inhibitors according to time structure may decrease their adverse effects and increase efficacy, compared to same dose administered blindly. © 2018 Nova Science Publishers, Inc.